Oral ribupatide produced up to 11.9% average weight loss at 26 weeks in a 2026 Phase 2 trial. It is a once-daily tablet built around a dual GLP-1/GIP peptide, not a copy of semaglutide or tirzepatide.
A peptide that can be taken by mouth sounds almost like a contradiction. Many peptides are easily broken down in the digestive tract, which is one reason so many well-known GLP-1 medicines are injected. Ribupatide is interesting because its developers are testing both a weekly injection and a daily oral tablet.
Why oral ribupatide matters
It combines two proven research targets with a less common delivery route.
What it is
A dual GLP-1/GIP agonist peptide in a once-daily tablet.
Best 26-week result
11.9% average weight loss in the 25 mg group.
Current status
Investigational Phase 2 evidence, not an approved product.
What did the 2026 oral ribupatide study find?
The randomized, double-blind Phase 2 trial enrolled 166 adults with obesity and without type 2 diabetes. Participants received oral ribupatide at 10, 25 or 50 mg once daily, or placebo, for 26 weeks.
The clearest treatment-policy results were:
| Daily group | Average weight change at week 26 |
|---|---|
| Ribupatide 10 mg | -6.7% |
| Ribupatide 25 mg | -11.9% |
| Ribupatide 50 mg | -11.4% |
| Placebo | -2.1% |
Up to 77.5% of participants reached at least 5% weight loss, 59.1% reached at least 10%, and 38.6% reached at least 15% across the ribupatide groups. The 25 mg and 50 mg curves had not clearly reached a plateau by week 26.
That last point matters. A 26-week result is a snapshot, not necessarily the final level. It also means the 11.9% and 11.4% numbers should not be treated as a permanent ranking between the two groups.
Why did 25 mg look slightly better than 50 mg?
At the final 26-week checkpoint, the 25 mg group had a slightly larger average change under the treatment-policy analysis. But the conference abstract says the 50 mg group had a steeper weight-loss path after week eight.
In plain English: one final number does not tell the whole story. Starting dose, dose increases, missed treatment and the way the statistical analysis handles discontinuations can all affect the result.
The study used two common ways to look at the data:
- The treatment-policy estimate asked what happened across participants, including events such as stopping treatment.
- The efficacy estimate focused more closely on the effect while following the planned treatment. Under that analysis, both 25 mg and 50 mg averaged 12.1% weight loss, compared with 2.3% for placebo.
This is why a good research summary should name the analysis instead of pulling the biggest percentage from a slide.
Is ribupatide really a peptide tablet?
Yes. Ribupatide, also called HRS9531 or KAI-9531, is described by its developers as a GLP-1/GIP dual receptor agonist peptide. The oral program uses a once-daily tablet, while a separate program studies a once-weekly injection.
That is different from oral candidates such as aleniglipron and orforglipron, which are small molecules rather than peptides. Both types can activate a GLP-1 receptor, but they are not the same kind of material.
| Candidate | Molecule type | Main targets | Studied format |
|---|---|---|---|
| Oral ribupatide | Peptide | GLP-1 + GIP | Daily tablet |
| Tirzepatide | Peptide | GIP + GLP-1 | Weekly injection |
| Semaglutide | Peptide | GLP-1 | Injection and an oral formulation |
| Aleniglipron | Small molecule | GLP-1 | Daily tablet |
For a simpler explanation of the two-target idea, see is tirzepatide a peptide? and our semaglutide vs tirzepatide comparison.
What side effects were reported?
The most common adverse events were nausea, diarrhea and vomiting. The conference report described most of them as mild or moderate. It also reported that none led to treatment discontinuation or a move to a lower dose in this trial.
Those are encouraging Phase 2 details, but they do not finish the safety story. A study of 166 people is not designed to find every uncommon event, and 26 weeks does not answer every long-term question. Larger and longer studies are needed.
What happens next for oral ribupatide?
Hengrui said it planned to move the oral program into Phase 3 in China. Kailera also described plans for a global Phase 2 program. The next studies need to show:
- whether the weight-loss curve continues beyond 26 weeks;
- whether a larger and more diverse population gets a similar result;
- how many people can remain on the planned dose;
- how the tablet compares with other oral GLP-1 programs; and
- whether manufacturing and absorption remain consistent at larger scale.
The online discussion around oral GLP-1s is already moving beyond needles. In a recent r/biotech discussion, people focused just as much on cost, insurance and access as on the delivery format. That is a useful commercial lesson: a pill only changes the market if it can also be made, distributed and accessed reliably.
Why oral delivery changes the research specification
The words “same receptor targets” do not mean two research materials are interchangeable. An oral peptide program adds questions about formulation, absorption and stability on top of the usual identity and purity questions.
Research buyers should verify:
- the exact compound name and molecular form;
- whether the material is raw peptide, formulated tablet material or another presentation;
- batch-specific HPLC purity and mass-spectrometry identity;
- peptide content or assay when required by the project;
- water, residual solvent and stability specifications when relevant; and
- the current batch COA, storage conditions, pack size and lead time.
Our peptide quality testing guide explains which test answers which question. The peptide COA vs specification sheet guide shows why buyers need both the promised limits and the actual batch result.
What the 26-week oral result means
Oral ribupatide’s headline is simple: up to 11.9% average weight loss at 26 weeks from a daily dual GLP-1/GIP peptide tablet. That puts oral peptide delivery into the 2026 obesity-research conversation in a serious way.
It remains an investigational program. For laboratory sourcing today, compare available dual-agonist research materials by exact identity, current batch testing, format and documentation rather than assuming every GLP-1/GIP product is equivalent.
Review current tirzepatide research specifications →
Sources and further reading
- American Diabetes Association: oral ribupatide Phase 2 results
- ClinicalTrials.gov: oral HRS9531 study NCT06841445
- Kailera and Hengrui Phase 2 trial description
This article explains public research reported through August 6, 2026. Oral ribupatide is investigational and is not offered here as a medicine or for personal use.
Frequently asked questions
What is oral ribupatide?
Oral ribupatide is an investigational once-daily tablet containing a dual GLP-1/GIP receptor agonist peptide. In a 2026 Phase 2 trial, the 25 mg group averaged 11.9% weight loss at 26 weeks.
How much weight loss did oral ribupatide produce?
At week 26, average weight loss was 6.7% with 10 mg, 11.9% with 25 mg and 11.4% with 50 mg, compared with 2.1% for placebo under the treatment-policy analysis.
Is ribupatide a peptide or a small molecule?
Ribupatide is a peptide. That makes its oral-tablet development especially notable because many peptide medicines are injected and peptides can be difficult to deliver through the digestive tract.
Is oral ribupatide the same as tirzepatide?
No. Both activate GLP-1 and GIP receptors, but ribupatide and tirzepatide are different peptide molecules with separate clinical programs and cannot be assumed to have identical results.
Is oral ribupatide approved?
No. Oral ribupatide remains investigational. The 2026 results came from a Phase 2 clinical trial and do not make the tablet an approved medicine or a product for personal use.
What should research buyers verify for a dual GLP-1/GIP peptide?
Verify the exact molecule and form, batch number, HPLC purity, mass-spectrometry identity, test dates, storage requirements and current batch COA before approving a research order.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.
← More gLP-1 & weight management guides · Have a question? Start an inquiry →